A Randomised, Double-blind, Placebo-controlled Study of the Safety, Pharmacokinetics and Exploratory Pharmacodynamics of AUT00206 for 28 Days as Adjunctive Therapy in Patients With Recently Diagnosed Schizophrenia

Trial Profile

A Randomised, Double-blind, Placebo-controlled Study of the Safety, Pharmacokinetics and Exploratory Pharmacodynamics of AUT00206 for 28 Days as Adjunctive Therapy in Patients With Recently Diagnosed Schizophrenia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 May 2017

At a glance

  • Drugs AUT 00206 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 18 May 2017 Status changed from planning to recruiting, according to an Autifony Therapeutics media release.
    • 10 Jan 2017 According to an Autifony Therapeutics media release, this trial will be conducted in collaboration with Dr Oliver Howes at the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) Kings College London.
    • 09 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top